BIOMAT Database Logo BIOMAT Database Logo

Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes. 2010

M S A Raja, and M Saldana, and C Goldsmith, and B J L Burton

UI MeSH Term Description Entries
D008268 Macular Degeneration Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms. Maculopathy,Maculopathy, Age-Related,Age-Related Macular Degeneration,Age-Related Maculopathies,Age-Related Maculopathy,Macular Degeneration, Age-Related,Macular Dystrophy,Maculopathies, Age-Related,Age Related Macular Degeneration,Age Related Maculopathies,Age Related Maculopathy,Age-Related Macular Degenerations,Degeneration, Macular,Dystrophy, Macular,Macular Degeneration, Age Related,Macular Degenerations,Macular Dystrophies,Maculopathies,Maculopathy, Age Related
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069579 Ranibizumab A recombinant humanized monoclonal antibody fragment that binds VEGF-A to prevent its binding to VEGFR-1 and VEGFR-2 receptors. This activity reduces vessel permeability and angiogenesis in the treatment of neovascular age-related MACULAR DEGENERATION. Lucentis,RhuFab V2,V2, RhuFab
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D014792 Visual Acuity Clarity or sharpness of OCULAR VISION or the ability of the eye to see fine details. Visual acuity depends on the functions of RETINA, neuronal transmission, and the interpretative ability of the brain. Normal visual acuity is expressed as 20/20 indicating that one can see at 20 feet what should normally be seen at that distance. Visual acuity can also be influenced by brightness, color, and contrast. Acuities, Visual,Acuity, Visual,Visual Acuities

Related Publications

M S A Raja, and M Saldana, and C Goldsmith, and B J L Burton
Intravitreal ranibizumab for patients with neovascular age-related macular degeneration with good baseline visual acuity.
January 2015, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde,
M S A Raja, and M Saldana, and C Goldsmith, and B J L Burton
Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12.
December 2011, Eye (London, England),
M S A Raja, and M Saldana, and C Goldsmith, and B J L Burton
Intravitreal ranibizumab for neovascular age-related macular degeneration patients with good baseline visual acuity and the predictive factors for visual outcomes.
April 2014, Journal francais d'ophtalmologie,
M S A Raja, and M Saldana, and C Goldsmith, and B J L Burton
Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
July 2012, Retina (Philadelphia, Pa.),
M S A Raja, and M Saldana, and C Goldsmith, and B J L Burton
Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision.
January 2011, Clinical & experimental ophthalmology,
M S A Raja, and M Saldana, and C Goldsmith, and B J L Burton
Comparison of intravitreal ranibizumab in phakic and pseudophakic neovascular age-related macular degeneration patients with good baseline visual acuity.
May 2014, Retina (Philadelphia, Pa.),
M S A Raja, and M Saldana, and C Goldsmith, and B J L Burton
Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity.
March 2014, Seminars in ophthalmology,
M S A Raja, and M Saldana, and C Goldsmith, and B J L Burton
Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degeneration.
January 2011, International journal of ophthalmology,
M S A Raja, and M Saldana, and C Goldsmith, and B J L Burton
FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity.
December 2012, Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,
M S A Raja, and M Saldana, and C Goldsmith, and B J L Burton
Functional outcomes after multiple treatments with ranibizumab in neovascular age-related macular degeneration beyond visual acuity.
June 2007, Clinical ophthalmology (Auckland, N.Z.),
Copied contents to your clipboard!